Coapt

Coapt operates at the intersection of medical devices, prosthetics, machine learning, and rehabilitation. Its primary differentiation is a clinically deployed myoelectric pattern-recognition system that decodes personalized muscle-signal patterns to control prosthetic hands, wrists, and elbows. Complete Control Gen2 is designed to work with virtually every prosthetic arm and hand component, giving it a compatibility-oriented position rather than tying users to a single hardware ecosystem. Control Coach adds an AI-based layer for evaluating signal quality, calibration, and control performance, while Control Companion provides mobile personalization and training tools. Coapt nevertheless competes broadly with established prosthetics manufacturers, component suppliers, and emerging neural-interface developers. Its distinction is the combination of FDA-cleared clinical hardware, adaptive software, wireless calibration, and a device-agnostic approach. The 2024 Myant partnership suggests an effort to extend beyond conventional electrode and prosthesis configurations into textile-based neural interfaces. Its small-company scale may support focused clinical engineering, but also implies fewer publicly visible resources than large medtech competitors.

Coapt’s trajectory shows a progression from focused prosthetic control technology toward a broader human-machine interface platform. Founded in 2012, the company introduced its first machine-learning-based pattern-recognition system in 2013, establishing an early technical position in intuitive upper-limb prosthesis control. The Complete Control Gen2 system subsequently expanded that foundation through personalized muscle-signal decoding, compatibility with a wide range of prosthetic components, and wireless calibration. Control Companion and Control Coach extend the product from embedded hardware into mobile support, user training, and AI-assisted performance improvement. The Jul 14, 2021 acquisition of Liberating Technologies was a notable expansion step, adding a prosthetics-focused organization and potentially broadening commercial and clinical reach. On Dec 5, 2024, the Myant partnership opened a new development direction involving textile-based neural interfaces and pain management. However, no funding history, valuation, employee-growth series, revenue figures, or recent hiring expansion is publicly available. The available employee range remains 11–50, while hiring information indicates no open positions were reported as of March 2020. Coapt’s measurable inflection points are therefore product diversification, acquisition, and partnership-led technology expansion rather than disclosed scale growth.